CDClément Danis

Clément Danis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Clément Danis has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Proline-Rich-Domain-Binding Single Domain Antibody Selectively Inhibits RNA-Induced Phase Separation of Tau

    by Simon Thiou, Leslie Martin, Evangelia Manousaki, Marine Nguyen, Justine Mortelecque, Leila Heidsieck, François-Xavier Cantrelle, David Blum, Valérie Buée-Scherrer, Luc Buée, et al.

    Phase separation mediates the formation of biomolecular condensates, which organize cellular processes such as synaptic plasticity in neurons. The neuronal protein tau undergoes phase separation under specific conditions, regulating synaptic vesicle clustering and microtubule dynamics. In vitro, tau phase separation is induced by cofactors such as polyethylene glycol (PEG) or RNA, mainly via weak multivalent electrostatic interactions. However, the molecular mechanisms governing the formation of tau phase separation, including domain specific contribution, remain unclear. In this study, we used eight single-domain antibodies (VHHs), targeting six distinct short sequences of tau, to explore the mechanisms of tau phase separation in vitro. By combining several biophysical methods, we evaluated the effect of each anti-tau VHH on tau phase separation. With PEG as an inducer, VHHs A31 and Z70 targeting the tau microtubule binding domain enhanced tau phase separation by increasing the droplet size. With RNA as an inducer, the effect of the VHHs was mixed: VHH F8-2 targeting the C-terminal domain promoted condensation, while VHH B1-1, which binds the proline-rich domain (PRD), abolished droplet formation. Nuclear magnetic resonance and surface plasmon resonance spectroscopies confirmed 1 to 1 binding of VHH B1-1 to the PRD, and competition assays with a PRD peptide restored phase separation, demonstrating mechanistic specificity. Our findings provide domain-resolved insights into the regulation of tau phase separation and introduce VHHs as selective probes to modulate biomolecular condensates in physiological and pathological contexts.


  • Caractérisation d'anticorps à domaine unique dirigés contre la protéine Tau

    by ClémEnt Danis

    Tau est une protéine neuronale intrinsèquement désordonnée. Sa principale fonction est de réguler la polymérisation de la tubuline et la formation des microtubules. La protéine Tau est d’autre part impliquée dans la maladie d’Alzheimer ainsi que dans d’autres maladies neurodégénératives communément appelées tauopathies. En conditions pathologiques, la protéine Tau est retrouvée sous forme agrégée en structures fibrillaires. Tau est le constituant majeur des filaments hélicoïdaux appariés retrouvés dans les dégénérescences neurofibrillaires observées dans les neurones et qui sont associées à ces maladies.Diverses hypothèses ont été explorées pour comprendre la cause de l’agrégation de la protéine Tau telles que des mutations au sein du gène codant pour la protéine, des modifications post-traductionnelles comme la phosphorylation ou l’acétylation, des facteurs de nucléation pouvant favoriser son agrégation, ou encore l’identification des régions intrinsèques pro-agrégantes de la protéine. Plus récemment des résultats ont montré que la protéine Tau sous forme agrégée était capable de se propager dans les différentes régions du cerveau par différents mécanismes de transfert inter-neuronal et pourrait adopter un comportement de type prion.Certaines approches immunothérapeutiques ont été proposées pour cibler la protéine Tau extracellulaire et intracellulaire et ainsi empêcher la formation des fibres pathologiques. Des études ont montré qu’il était possible, en utilisant des anticorps ciblant des épitopes spécifiques de Tau, de réduire la formation de fibres et d’améliorer les fonctions cognitives chez des modèles de souris développant une tauopathie.Dans ce contexte, notre but est de développer et caractériser des anticorps à domaine unique dirigés contre différentes formes de protéines Tau, afin de mieux comprendre les mécanismes liés à son agrégation et à sa propagation dans un contexte pathologique, mais également comme outils pour explorer de nouvelles stratégies thérapeutiques. Les anticorps à domaine unique, également appelés VHHs (pour « variable heavy chain of the heavy chain only antibody ») sont constitués d’un domaine unique qui correspond à la chaine variable lourde retrouvée dans les immunoglobulines G de type 2 et 3 de la famille des Camelidae. De par leur petite taille, les VHHs échappent à certaines contraintes et peuvent être plus facilement utilisés dans des expériences in vitro et in vivo. Ils ont également été décrits comme étant capable de passer au travers de la barrière hématoencéphalique. Enfin, ils sont produits de manière peu coûteuse en système bactérien et peuvent être modifiés de manière recombinante pour en adapter les propriétés biochimiques.Dans un premier temps, et en collaboration avec la société Hybrigenics services, des VHHs ciblant les différentes formes de Tau ont été obtenus par phage display à partir d’une banque naïve synthétique. Les épitopes ont été identifiés par résonance magnétique nucléaire et les paramètres d’affinité pour chaque interaction VHH-Tau ont été déterminés par résonance plasmonique de surface.Dans un deuxième temps, des premiers tests d’agrégation de la protéine Tau ont été réalisés, dans le but d’évaluer l’effet des VHHs sur cette agrégation au regard de leur épitope et de leur affinité. L’un des VHHs, appelé E4-1 et ciblant les régions pro-agrégantes de Tau, est capable d’inhiber son agrégation in vitro. Toujours en collaboration avec Hybrigenics, le VHH E4-1 a été optimisé pour permettre son expression intracellulaire. Un mutant appelé VHH Z70 a été obtenu. Ce mutant a la particularité d’inhiber de façon plus importante l’agrégation de Tau in vitro mais il est également capable d’empêcher l’agrégation intracellulaire de Tau dans un modèle cellulaire de nucléation

  • Open Access

    A proline-rich-domain-binding single domain antibody selectively inhibits RNA-induced liquid-liquid phase separation of tau

    by Simon Thiou, Leslie Martin, Evangelia Manousaki, Marine Nguyen, Justine Mortelecque, Leila Heidsieck, François-Xavier Cantrelle, David Blum, Valérie Buée-Scherrer, Luc Buée, et al.

    Liquid-liquid phase separation (LLPS) mediates the formation of biomolecular condensates, which organize cellular processes such as synaptic plasticity and stress response. The neuronal microtubule-associated protein tau undergoes LLPS under specific conditions, regulating synaptic vesicle clustering and microtubule dynamics. In vitro , tau LLPS is induced by cofactors such as polyethylene glycol (PEG) or RNA, mainly via weak multivalent electrostatic interactions. However, the molecular mechanisms governing the formation of tau LLPS, including domain specific contribution, remain unclear. In this study, we used eight single-domain antibodies (VHHs), targeting six distinct short sequences of tau, to explore the mechanisms of tau LLPS in vitro . By combining several biophysical methods, we evaluated the effect of each anti-tau VHH on tau LLPS with two main LLPS inducers, PEG (molecular crowding) and RNA (complex coacervation). With PEG as an inducer, all VHHs targeting tau enhanced tau LLPS formation, regardless of their affinity for tau. With RNA as an inducer, the effect of the VHHs was mixed: VHHs targeting the C-terminal domain promoted condensation, while VHH B1-1, which binds the proline-rich domain (PRD; including residues ( 221 REPKKVAVVRTP 232 ), abolished droplet formation. NMR and surface plasmon resonance confirmed 1 to 1 binding of VHH B1-1 to the PRD, and competition assays with a PRD peptide restored LLPS, demonstrating mechanistic specificity. This result underscores the importance of this region in tau LLPS formation. Our findings provide domain-resolved insights into the regulation of tau LLPS and demonstrate the potential of VHHs as tools to selectively modulate biomolecular condensates in physiological and pathological contexts.

  • Open Access

    Inhibition of tau neuronal internalization using anti-tau single domain antibodies

    by Clément Danis, Elian Dupré, Thomas Bouillet, Marine Denéchaud, Camille Lefebvre, Marine Nguyen, Justine Mortelecque, François-Xavier Cantrelle, Jean-Christophe Rain, Xavier Hanoulle, et al.

    In Alzheimer’s disease, tau pathology spreads across brain regions as the disease progresses. Intracellular tau can be released and taken up by nearby neurons. We evaluated single domain anti-tau antibodies, also called VHHs, as inhibitors of tau internalization. We identified three VHH inhibitors of tau uptake: A31, H3-2, and Z70mut1. These VHHs compete with the membrane protein LRP1, a major receptor mediating neuronal uptake of tau. A31 and Z70mut1 bind to microtubule binding domain repeats, which are involved in the interaction with LRP1. VHH H3-2 is the only VHH from our library that reduces the internalization of both monomeric tau and tau fibrils. VHH H3-2 binds a C-terminal tau epitope with high affinity. Its three-dimensional structure in complex with a tau peptide reveals a unique binding mode as a VHH-swapped dimer. These anti-tau VHHs are interesting tools to study tau prion-like propagation in tauopathies and potentially develop novel biotherapies.


  • Conformation-Driven Phase Separation in the Linker Domain of Focal Adhesion Kinases

    by Lucy Martin, Daniela P. Freitas, Emmanuelle Boll, Alain Brans, Justine Mortelecque, François-Xavier Cantrelle, Pierre Dourlen, Cláudio M. Gomes, Clément Danis, Isabelle Landrieu

    Protein tyrosine kinase 2 (Pyk2), also known as focal adhesion kinase 2, and focal adhesion kinase 1 (Fak1) are two related nonreceptor tyrosine kinases (hereafter referred to as FAKs). Here, we focused on characterizing a linker region of the FAK proteins (hereafter referred to as FAK KFL for Kinase FAT Linker), which in the case of Pyk2 has previously been shown to play a functional role in calcium sensing through its interaction with calmodulin. Using structural nuclear magnetic resonance spectroscopy, we provide chemical shift assignments for the FAK KFLs, defining their conformational properties. Analysis of the FAK KFL conformations revealed their predominantly disordered nature, except for well-defined segments with a significant tendency to form α-helices, which were modeled to form homodimeric interfaces. In addition, we showed that the FAK KFL segments form condensates in vitro under high crowding conditions. By directly comparing the conformational properties of the Pyk2 and Fak1 KFL domains and providing structural data, this study provides valuable insights into the structural basis of FAK KFL interactions. Furthermore, the results show that disordered segments in proteins within the focal adhesion complex undergo phase separation, a process of potential biological significance due to protein clustering.


  • Open Access

    Aggregate-selective removal of pathological tau by clustering-activated degraders

    by Jonathan Benn, Shi Cheng, Sophie Keeling, Annabel E. Smith, Marina J. Vaysburd, Dorothea Böken, Lauren V. C. Miller, Taxiarchis Katsinelos, Catarina Franco, Elian Dupré, et al.

    Selective degradation of pathological protein aggregates while sparing monomeric forms is of major therapeutic interest. The E3 ligase tripartite motif–containing protein 21 (TRIM21) degrades antibody-bound proteins in an assembly state–specific manner due to the requirement of TRIM21 RING domain clustering for activation, yet effective targeting of intracellular assemblies remains challenging. Here, we fused the RING domain of TRIM21 to a target-specific nanobody to create intracellularly expressed constructs capable of selectively degrading assembled proteins. We evaluated this approach against green fluorescent protein–tagged histone 2B (H2B-GFP) and tau, a protein that undergoes pathological aggregation in Alzheimer’s and other neurodegenerative diseases. RING-nanobody degraders prevented or reversed tau aggregation in culture and in vivo, with minimal impact on monomeric tau. This approach may have therapeutic potential for the many disorders driven by intracellular protein aggregation.


  • Open Access

    A selection and optimization strategy for single-domain antibodies targeting the PHF6 linear peptide within the tau intrinsically disordered protein

    by Justine Mortelecque, Orgeta Zejneli, Séverine Bégard, Margarida C. Simões, Lea ElHajjar, Marine Nguyen, François-Xavier Cantrelle, Xavier Hanoulle, Jean-Christophe Rain, Morvane Colin, et al.


  • Open Access

    Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies

    by Elodie Leroux, Romain Perbet, Raphaëlle Caillierez, Kevin Richetin, Sarah Lieger, Jeanne Espourteille, Thomas Bouillet, Séverine Bégard, Clément Danis, Anne Loyens, et al.